ARTICLE | Deals
Aiolos team, VCs steer asthma start-up into quick $1B sale to GSK
Syndicate wins an exit 11 weeks after announcement of series A round to fund development of Phase II-ready asset from Hengrui
January 10, 2024 12:07 AM UTC
Just 11 weeks after Aiolos announced a $245 million series A round to support development of its in-licensed asset for asthma, the start-up’s leadership team has negotiated a $1 billion sale to GSK.
The British pharma will gain AIO-001, a long-acting anti-TSLP antibody that is ready for Phase II testing. Aiolos holds worldwide, ex-Greater China rights to the product under a deal with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Shanghai:600276)...